From: Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
Cost-effectiveness | MET + SU | MET + SAXA | Difference |
---|---|---|---|
Discounted costs | 10,694,769 (10,694.8) | 12,327,677 (12,327.7) | 1,632,909 (1,632.9) |
Discounted QALYs | 9,322 (9.32) | 9,544 (9.54) | 221 (0.22) |
Discounted LYG | 20,765 (20.76) | 20,845 (20.84) | 80 (0.08) |
Cost per QALY | Â | Â | 7,374.2 |
Cost per LYG | Â | Â | 20,490.3 |